Amneal (AMRX) Q3 2026 earnings review
Amneal raises its profit outlook, but cuts its cash plan
Amneal's newer complex generics and branded drugs are lifting profit, while stockpiling inventory and deal costs eat into cash. The generic and specialty drugmaker grew third-quarter revenue 10%, as ~19% growth across its two drug-making divisions overcame an expected drop in distribution. Co-chief executives Chirag and Chintu Patel raised the full-year profit outlook for a third straight quarter, though by our math the revenue plan points to barely 1% growth in the fourth quarter.
| Revenue | $862.7M +10.0% from a year ago |
|---|---|
| Profit per share, excluding one-offs | $0.26 +53% from a year ago |
| Full-year EBITDA outlook, excluding one-offs | Raised $42.5M middle of the range: 17.3% growth |
| Full-year operating cash flow outlook | Cut $25M to $325–375M on inventory build |
⚖️ Verdict: 🟢 Bullish
The story got better because core drug sales sped up and management raised the full-year EBITDA target by $43 million. One caution: Amneal had to cut its full-year operating cash flow plan by $25 million as inventory grew, and closing the Kashiv acquisition pushed net debt up to 3.9 times EBITDA.
The question now is whether the cash drain is a temporary inventory build for new launches or a lasting cost of growth and deal integration. If it is temporary, fourth-quarter collections will surge; if it is structural, the company will miss its lowered cash target too. Fourth-quarter operating cash flow, which needs to hit $300 million by our math to reach the midpoint, will settle it.
🐂 Bull Case
New Complex Drugs Accelerated Core Sales
Amneal's largest division is Affordable Medicines, which sells retail generic pills, hospital injections, and biosimilars (lower-cost versions of complex biologic drugs). Sales in this unit rose 18.8% from a year ago to $547.1 million, accelerating from 13.0% growth in the second quarter. The company said growth was "driven by biosimilars, women’s health patches, and new launches", and it launched its lanreotide cancer injection in September.
This acceleration matters because complex products offset the tough comparison at AvKARE, Amneal's government and retail distribution unit. AvKARE sales fell 16.7% to $165.3 million "due to a non-recurring cardiovascular product launch in the prior year", the drugmaker said. By our math, excluding AvKARE, combined sales in the two drug-making units rose 19.0% from a year ago.
What to watch: the quarterly filing's revenue breakdown by dosage form. If skin patches and injections keep taking at least 15% of total revenue, the shift away from cheap generic pills is holding.
Branded Drugs Lifted Profit Margins
The Specialty division sells branded drugs for nerve and hormone disorders, including Crexont for Parkinson's disease and the Brekiya migraine injector. Segment revenue grew 20.0% from a year ago to $150.3 million. Because Specialty carries an 81.8% gross margin excluding one-offs, its growth lifted company-wide profit margins while operating expenses fell as a share of sales.
- Operating margin excluding one-offs: 22.3%, up 3.8 percentage points from a year ago
- Selling and overhead costs excluding one-offs: 14.7% of revenue, down 1.5 percentage points
- Research and development excluding one-offs: 6.2% of revenue, down 1.5 percentage points
- Reported cost of making products: 61.3% of revenue, down 3.8 percentage points
What to watch: fourth-quarter operating margin excluding one-offs. Holding above 20% during the seasonal fourth-quarter marketing push would show that branded drug profitability is outrunning generic price erosion.
Third Straight Profit Outlook Raise
Amneal raised its full-year profit outlook for a third consecutive quarter, lifting the middle of its target for EBITDA (earnings before interest, taxes, depreciation, and amortization) excluding one-offs by $42.5 million. An August debt repricing also helped per-share profit by cutting interest rates on its term loan for a second time this year, lowering net interest expense by 6.2% to $58.9 million despite new borrowings.
The drugmaker also raised its full-year revenue forecast by $50 million, to $3.15–3.25 billion. By our math, the middle of that range leaves $818.6 million for the fourth quarter, or 0.5% growth from a year ago. Because third-quarter revenue just grew 10.0%, the fourth-quarter target looks cautious even against a tough prior-year comparison.
What to watch: fourth-quarter revenue against the implied $818.6 million midpoint. Another beat would confirm management's habit of setting conservative targets.
🐻 Bear Case
Cash Flow Target Cut as Inventory Builds
Last quarter Amneal kept its $350–400 million full-year operating cash flow plan unchanged even though first-half cash flow was negative $48.0 million. This quarter the company cut that plan by $25 million, to $325–375 million, "reflecting working capital, including higher inventory levels in key growth areas", the release said. It also raised estimated Kashiv deal and integration cash costs to $40 million from $30 million.
Operating cash flow turned positive in the third quarter at $98.3 million by our math, bringing the nine-month total to $50.3 million against $209.7 million a year ago. Even after the cut, reaching the $350 million midpoint requires $299.7 million of operating cash flow in the fourth quarter by our math. That is more than double the $130.3 million generated in the fourth quarter of 2025.
What to watch: fourth-quarter operating cash flow and inventory levels. Falling short of the lowered $325 million floor would show that new drug launches require more permanent working capital than planned.
Kashiv Deal Pushed Up Debt and Share Count
"The Kashiv integration is proceeding well, and we are excited about the long-term growth potential in biosimilars," co-chief executives Chirag and Chintu Patel said. Amneal closed the purchase of Kashiv, a biosimilar maker partially owned by Amneal insiders, during the third quarter for $421.0 million in net cash plus stock and future milestone payments.
- Net debt: $3.07 billion, up 27.4% from $2.41 billion at year-end 2025
- Net debt to EBITDA excluding one-offs: 3.9 times, up from 3.5 times at year-end and 3.6 times in Q2
- Related-party contingent consideration liability: $383.0 million added to the balance sheet
- Press release disclosure of Kashiv's standalone revenue or profit contribution: none
To pay for the deal, the company borrowed $350.0 million in new term loans and drew $180.0 million on its credit line, moving it further from its goal of reducing net debt below 3.0 times EBITDA by 2028.
What to watch: the business combination note in the third-quarter filing. Investors need Kashiv's standalone revenue and profit numbers to judge whether the insider deal is paying for itself.
Risks this quarter didn't answer
Four standing concerns and watch items could not be read from the earnings release because the details live in the quarterly filing or presentation.
- Crexont vs Rytary sales split: the release did not give product-level revenue, leaving open how much of Crexont's growth comes from switching Rytary patients before generic competition hits.
- Skin patch and injectable revenue share: disaggregated revenue by dosage form awaits the quarterly filing.
- Customer concentration: three buyers accounted for 85% of receivables in the second quarter; the third-quarter concentration table awaits the filing.
- Proposed 2028 generic drug tariffs: mentioned only in standard risk-factor boilerplate, with no cost estimate.
👓 Other Themes
India Factory Restored After July Flood
Heavy rain in July caused water damage at one of Amneal's manufacturing plants in India. "Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations," the drugmaker said. The company recorded $5.4 million in property and inventory loss charges in the third quarter and still raised its full-year profit outlook.
💲 Other KPIs
Uncollected customer bills rose 14.9% from a year ago, outpacing the 10.0% increase in third-quarter revenue. Compared with the second quarter, receivables edged down slightly from $1,020.4 million, but have absorbed $122.4 million of cash over the first nine months of 2026.
Stockpiled drugs and raw materials grew 15.2% from a year ago and rose from $678.0 million in the second quarter and $606.3 million at year-end. Building stock for new launches and integrating Kashiv consumed $158.3 million of cash over the first nine months, more than double last year's $66.8 million outflow.
The share count used to calculate profit per share excluding one-offs rose 7.3% from a year ago and jumped from 328.1 million in the second quarter. The increase came from shares issued to close the Kashiv acquisition, which also pushed GAAP diluted shares to 335.7 million.
🔮 Guidance
Raised. The middle of the range moved up $50 million, calling for 6.0% growth for the full year. By our math, that leaves $818.6 million for the fourth quarter, or 0.5% growth from a year ago against 10.0% in the third quarter. It is the second $50 million raise in two quarters: +$0M, +$50M, +$50M.
Raised. The middle of the target for EBITDA excluding one-offs rose $42.5 million, pointing to 17.3% growth this year. By our math, that leaves $192.0 million for the fourth quarter, up 9.6% from a year ago. It is the third raise in three quarters, and the largest yet: +$15M, +$10M, +$42.5M.
Raised. The middle of the profit-per-share plan moved up $0.05 to $1.06, or 27.7% growth for the year, assuming about 340 million shares. By our math, that leaves $0.23 for the fourth quarter, up 9.5% from a year ago. Third raise in three quarters: +$0.02, +$0.01, +$0.05.
Cut. Management lowered the middle of the cash flow plan by $25 million, which now points to 2.9% growth for the year. Because nine-month cash flow is only $50.3 million, by our math the plan still requires $299.7 million in the fourth quarter, up 130.0% from last year's fourth quarter.
Cut. The middle of the range fell $25 million due to higher inventory and working capital needs. The target excludes about $36 million of opioid legal settlements and about $40 million of Kashiv deal and integration costs, up from $30 million estimated last quarter.
Unchanged. The company still plans to spend about $150 million on property, plant, equipment, and equipment deposits this year. Through nine months, it has spent $99.0 million ($70.7 million on purchases and $28.4 million on deposits), leaving about $51.0 million for the fourth quarter.
❓ Key Questions
How much revenue and profit did Kashiv contribute in Q3?
Amneal closed the related-party Kashiv acquisition in the third quarter and raised its full-year outlook, but the release does not state how much revenue or EBITDA Kashiv added after closing.
How will Q4 generate $300 million of operating cash flow?
Even after cutting the full-year operating cash flow outlook by $25 million, hitting the $350 million midpoint requires $299.7 million in the fourth quarter, more than double last year's fourth quarter.
What were Crexont and Rytary sales in the third quarter?
Specialty grew 20.0%, but without product-level numbers investors cannot see how fast Rytary is shrinking or how much of Crexont's growth comes from switching existing Rytary patients.
What triggered the $8 million government investigation charge?
Footnote 3 of the non-GAAP tables discloses a new $8.0 million legal charge for government investigations in the third quarter without naming the product or agency involved.